Beta Bionics Q2 Sales Jump 38%, Raises Gross Margin Outlook
BBNX sits 77% above its 52-week low of $8.8.
Summary
Beta Bionics delivered strong Q2 results with net sales of $32.0 million, a 38% increase year-over-year, driven by a 153% surge in the higher-margin pharmacy channel. Gross margin expanded 524 basis points to 59.0%, and the company raised its full-year gross margin guidance to 58.5%-59.5%. New patient starts grew 10-20% sequentially, with nearly 70% coming from multiple daily injections, signaling market share gains. The company also initiated a pivotal trial for its iLet system in type 2 diabetes, targeting a mid-2027 label expansion, and updated its Mint patch pump commercialization timeline to end of Q2 2027. With $225.2 million in cash, the runway extends well beyond these milestones. The raised margin outlook and pipeline progress reinforce the growth narrative, though operating losses remain substantial at $25.6 million.
At the time of this announcement, BBNX was trading at $15.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $676M. The 52-week trading range was $8.80 to $32.71. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.